Cerebral Haemorrhage Prevention
Cerebral Haemorrhage Prevention
Prevention after a cerebral haemorrhage is unusual among medical problems in that it has a clear centre. Blood pressure control is the measure with the strongest evidence behind it, it applies to the commonest mechanism, and it can be pursued with numbers rather than intentions. Around it sit a smaller number of decisions — what to do about a blood thinner, how to handle alcohol and stimulant drugs, and when it is worth looking at other members of a family — that are genuinely individual. What prevention does not consist of is a long list of things to be afraid of, and it is worth saying so, because fear is a poor substitute for treatment.
Blood pressure: the part that is known to work
If one thing is carried away from this page it should be this. High blood pressure is the strongest modifiable factor behind a cerebral haemorrhage, and lowering it is the intervention with the clearest evidence for reducing the risk of a further bleed. That makes it different in kind from most of what surrounds it: it is not a precaution, it is a treatment with a target, a measurement and a review.
In practice this means pressure is brought to a target agreed with the treating team rather than to whatever it happens to be, it is measured at home as well as in clinic so that the average rather than the occasion is treated, and the regimen is adjusted until the readings say it is working. The unglamorous details decide whether this succeeds: taking the medication at the same time each day, keeping a record rather than remembering an impression, reducing salt, moderating alcohol, staying active, and losing weight where it is relevant.
One caution belongs with the enthusiasm. Pressure should not be driven down aggressively in the weeks after a haemorrhage without discussion, because the brain that has just been injured is sensitive to low perfusion as well as to high. The aim is sustained, well-tolerated control rather than the lowest achievable number — and that is a conversation to have with the treating team rather than a target to pursue alone.
Medication: deliberate decisions, not impulses
The medication questions after a haemorrhage are the ones patients worry about most, and they deserve to be answered rather than left open. The first is the anticoagulant: whether it can be restarted, and when. That decision belongs to the stroke team together with the team that prescribed it, because it weighs the risk of bleeding again against the risk of the stroke or embolism the drug was preventing. It is not a decision to make at home, in either direction.
The second is antiplatelet treatment. Where it was being taken for prevention and the indication is not strong, it is often reasonable to leave it off; where it is needed for a recent coronary stent or a similar indication, the alternatives have to be discussed with the team that placed it, because stopping it carries its own risk. The third is a category patients rarely think of: non-steroidal anti-inflammatory drugs, taken for ordinary aches, increase bleeding risk and interact with both pressure control and kidney function.
Alcohol, stimulants and the risks that are genuinely avoidable
Heavy alcohol use is associated with an increased risk of haemorrhagic stroke, and the association is stronger than for most other lifestyle factors discussed in this context. Binge drinking appears to carry particular risk, which fits the mechanism: an abrupt rise in blood pressure, together with effects on clotting, in a vessel that is already fragile. Moderation here is not a moral suggestion but a straightforward risk reduction.
Cocaine and other sympathomimetic drugs are a recognised direct cause of cerebral haemorrhage, and they act in two ways at once — by driving pressure up sharply and by injuring the vessel wall. This is a cause that is disproportionately represented among younger patients, and it is one of the reasons a bleed in a young adult with no history of high blood pressure should prompt questions that a routine history may not ask. Where substance use is part of the picture, treatment of that problem is part of the prevention of the next bleed, not a separate matter.
Prevention after a bleed: what changes
Once a haemorrhage has happened, the priorities are not identical to those of primary prevention, because the question is no longer who might bleed but what will make this particular patient bleed again.
The centre of gravity remains blood pressure, and it is pursued more attentively than before, because the brain now contains tissue that is more vulnerable to both high and low pressure. The cause matters more than it did: where it was amyloid angiopathy, the risk of recurrence is higher and the tolerance for unnecessary antithrombotic treatment is lower; where it was a structural lesion that has since been treated, the risk profile is different again. Treating the conditions that travel with vascular disease — diabetes, kidney disease, sleep apnoea, high cholesterol where relevant — is worthwhile for its own reasons and contributes here. And rehabilitation is not only about recovery: returning to activity, including exercise, is part of reducing risk rather than a reward for having recovered.
Should relatives be screened?
Usually not, and this is worth stating clearly because anxiety about family risk is common and the reassurance matters. The two common mechanisms — the small-vessel disease of high blood pressure and the amyloid angiopathy of age — are not inherited conditions in the ordinary sense, and the presence of these risk factors in a family reflects shared circumstances as much as shared genes. Screening relatives of a patient with a typical haemorrhage is not recommended.
The exceptions are specific and can be recognised. When a bleed occurs in a young patient with a family history of similar events, or when there are features suggesting an inherited disorder of connective tissue or of the small vessels, genetic assessment may be appropriate. When a patient has a condition in which vascular malformations are known to occur in multiple family members, screening of relatives is part of standard care and should be arranged rather than assumed. In all of these situations the answer is a specialist assessment, not a general rule.
What a written prevention plan contains
A plan worth having is short enough to be read and specific enough to be acted on. It states the blood pressure target and the medicines that achieve it, with the monitoring that confirms it is being achieved. It records the established cause of the haemorrhage and what evidence it rested on, because that single line determines how much of the rest matters. It records the decision about antithrombotic medication, who made it, and what would justify revisiting it. It lists the modifiable factors being addressed — alcohol, activity, weight, sleep apnoea, glucose — and what is actually being done about each rather than only that they are important. And it names who to contact if the pressure stops responding, if new symptoms appear, or if another clinician proposes a blood thinner.
Patients who carry such a plan tend to do better for an unsentimental reason: it makes the decision that matters most — blood pressure, every day — something that can be checked rather than remembered, and it makes the decisions that need expertise arrive at the right desk. It is a modest document with more influence on the next ten years than most of what happens in the first week.